High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

Share this content:
There was a slight increase in HbA1c in patients who took high-intensity statins.
There was a slight increase in HbA1c in patients who took high-intensity statins.
The following article is part of conference coverage from the American Diabetes Association's 78th Scientific Sessions (ADA 2018) in Orlando,Florida. Endocrinology Advisor's staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back for the latest news from ADA 2018.

ORLANDO — Research presented at the 78th Scientific Session of the American Diabetes Association, held June 22-26, 2018 in Orlando, Florida, reports that in individuals with type 2 diabetes, the dosage of statins, high-intensity vs low-intensity, did not significantly worsen glucose homeostasis.

These results come from a randomized study evaluating the effects of statins on glucose homeostasis and glycemic control in individuals with type 2 diabetes who were already prescribed a statin medication, simvastatin up to 20mg/d. The low dose group (n=49) took simvastatin up to 20 mg per day for 12 weeks, and the high-intensity group (n=51) took daily atorvastatin 40 mg for 6 weeks and then 80 mg per day for 6 weeks, if tolerated. Assessments were taken at baseline, 6 weeks, and 12 weeks. Fasting plasma glucose, glycated hemoglobin (HbA1c), fasting plasma insulin, homeostatic model assessment-insulin resistance [HOMA-IR], and homeostatic model assessment- β-cell function [HOMA-B] were analyzed. Baseline glucose homeostasis was similar between both groups. 

Fasting plasma glucose, fasting plasma insulin, HOMA-IR, and HOMA-B showed no significant difference between the study arms at 6 weeks and 12 weeks. There was a minor increase in HbA1c at both 6 and 12 weeks in the high-intensity group.

The presenter of the study concluded “there was no significant deterioration in glucose homeostasis with high-intensity statins as compared to low dose statins in patients with type 2 diabetes.”

Disclosure 

N. Thongtang: Other Relationship; Self; Pfizer Inc.. S. Sriussadaporn: None. N. Tangkittikasem: None.

For more coverage of ADA 2018, click here. 

Reference

Thongtang N, Sriussadaporn S, Tangkittikasem, N. Effects of high-intensity statins on glucose homeostasis in patients with type 2 diabetes. Poster presentation at: ADA 2018 78th Scientific Sessions; June 22-26, 2018; Orlando, FL. Poster 627.

You must be a registered member of Endocrinology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-Newsletters